---
title: "Chugai Shares Drop Following Termination of Drug Development"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280081356.md"
description: "Chugai Pharmaceutical's shares fell 7.3%, the largest intraday drop since August 2025, following the announcement to halt the development of an experimental drug for muscle weakness diseases. This decision has raised investor concerns, negatively affecting the company's market performance."
datetime: "2026-03-23T01:36:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280081356.md)
  - [en](https://longbridge.com/en/news/280081356.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280081356.md)
generator: "portal-rs"
---

# Chugai Shares Drop Following Termination of Drug Development

Chugai Pharmaceutical experienced a significant drop in its stock value, falling 7.3%, marking the largest intraday decline since August 2025. Bloomberg posted on X that the decline followed the company's announcement to halt the development of an experimental drug aimed at treating specific diseases that lead to muscle weakness. The decision to discontinue the drug's development has raised concerns among investors, impacting the company's market performance.

### Related Stocks

- [1964.JP](https://longbridge.com/en/quote/1964.JP.md)
- [4519.JP](https://longbridge.com/en/quote/4519.JP.md)
- [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md)
- [1491.JP](https://longbridge.com/en/quote/1491.JP.md)

## Related News & Research

- [Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema](https://longbridge.com/en/news/296868472.md)
- [Chugai seeks Japan approval for Enspryng to prevent MOGAD relapses](https://longbridge.com/en/news/294463834.md)
- [Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services](https://longbridge.com/en/news/297162314.md)
- [14:52 ETAPhA Foundation Announces 2026 Pinnacle Award Recipients](https://longbridge.com/en/news/297361032.md)
- [Oost NL provides follow-on financing for GlycoTherapeutics to advance cancer drug candidate](https://longbridge.com/en/news/297175970.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**